Omega-3 Recommendations Updated: High-Dose Icosapent Ethyl for High-Risk Patients
European Atherosclerosis Society has shared a post on LinkedIn:
“The recommendation for the use of omega 3 polyunsaturated fatty acids from 2019 has changed in the Focussed Update by now explicitly stating that only high-dose icosapent ethyl should be considered for high-risk or very high-risk patients with elevated triglyceride levels.
The rationale for this revision was the negative STRENGTH trial which failed to demonstrate benefit of a combined EPA and DHA preparation which is in contrast to the REDUCE-it trial which showed a reduction in cardiovascular events in high risk patients with TG levels of 1,5-5,6 mmol/L with icosapent ethyl which is a pure EPA compound.
Moreover there is a new recommendation for patients with severe hypertriglyceridaemia due to familial chylomicronaemia syndrome based on the results of the randomized placebo controlled APPROACH trial which showed a 77% decrease in TG levels and reduction of pancreatitis in FCS patients treated with Volanesorsen an antisense Oligoligonucleotide targeting apoC3.
This led to the recommendation that volenasoren should be considered in FCS patients with severe hypertriglyceridemia to lower triglyceride levels and reduce the risk of pancreatitis.”
Learn more here.
Discover more on Hemostasis Today.
-
Jun 9, 2026, 09:49Lee Severin: Why Patients Love Platelet-Rich Plasma
-
Jun 9, 2026, 09:42Lorena Gerlach: Blood Transportation Duty on this Muggy Spring Day
-
Jun 9, 2026, 08:54Shujha Abbas: Understanding the Real Cost of Gene Therapie
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026
-
Jun 9, 2026, 03:14Rucha Patil: A Collaborative Initiative to Transform Rare Blood Disorder Care in Rajasthan
-
Jun 9, 2026, 02:28Andreas Calatzis: Chasing Biologically Inactive Heparin?
-
Jun 9, 2026, 02:16Javier Lagos Servellon: Reflections on Completing the University of Bern’s Stroke Medicine Program
-
Jun 8, 2026, 17:50From Bleeding to Swelling – A Shared Therapeutic Revolution in Rare Diseases – RPTH Journal